Alvogen Korea surpassed ₩200 billion in annual sales for the first time since its launch in Korea. Qsymia, an obesity treatment drug released at the beginning of last year, and the obesity treatment Qsymia, which was released earlier last year, produced the largest sales.

According to the Financial Supervisory Service on the 7th, Alvogen Korea's sales last year reached ₩211.1 billion, up 11.3% from the previous year. For the first time since the establishment of the branch, annual sales exceeded the ₩200 billion. Operating profit was ₩17.3 billion, up 19.3% from the previous year.

The predecessor of Alvogen Korea is KEUNWHA, founded in 1958. Alvogen Group,